Of mice and men: A comparative study of cancer-associated fibroblasts in mammary carcinoma

Upsala Journal of Medical Sciences

Volumn 117, Issue 2, 2012, Pages 196-201

  Roswall, Pernilla ^a   Pietras, Kristian ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarkers; Breast neoplasms; Fibroblast

Indexed keywords

ANIMAL; ARTICLE; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; PATHOLOGY; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC;

EID: 84859908853     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2012.658973     Document Type: Article

References (19)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that over-expresses her2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in her2-positive breast cancer. N Engl J Med. 2005;353:1659-72. (Pubitemid 41464705)
3. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in kras are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-9.
4. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. Kras mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
5. Pietras K, Ostman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res. 2010;316:1324-31.
6. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7:513-20. (Pubitemid 40799245)
7. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle t oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954-61.
8. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, et al. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007;5:323-8. (Pubitemid 47265551)
9. Fluck MM, Schaffhausen BS. Lessons in signaling and tumor-igenesis from polyomavirus middle t antigen. Microbiol Mol Biol Rev. 2009;73:542-63.
10. Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, et al. Mmtv mouse models and the diagnostic values of mmtv-like sequences in human breast cancer. Expert Rev Mol Diagn. 2009;9:423-40.
11. Ponten F, Jirstrom K, Uhlen M. The human protein atlas\-a tool for pathology. J Pathol. 2008;216:387-93.
12. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, et al. The mammary pathology of genetically engineered mice: The consensus report and recommendations from the annapolis meeting. Oncogene. 2000;19:968-88. (Pubitemid 30153780)
13. Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, et al. Paracrine signaling by platelet-derived growth factor-cc promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 2009;69: 369-78.
14. Anderberg C, Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle. 2009;8:1461-2.
15. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006;5:1640-6.
16. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449:557-63. (Pubitemid 47525152)
17. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. Vegfr1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820-7. (Pubitemid 41753060)
18. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009;15:68-74.
19. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518-27. (Pubitemid 351655218)